UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

Effectiveness of durvalumab versus chemotherapy in metastatic urothelial cancer: an observational, indirect comparison

Nordstrom, BL; Oguz, M; Chu, BC; Ouwens, M; Arkenau, H-T; Klein, AB; (2020) Effectiveness of durvalumab versus chemotherapy in metastatic urothelial cancer: an observational, indirect comparison. Journal of Comparative Effectiveness Research , 9 (3) pp. 191-199. 10.2217/cer-2019-0163. Green open access

[thumbnail of cer-2019-0163.pdf]
Preview
Text
cer-2019-0163.pdf - Published Version

Download (959kB) | Preview

Abstract

Aim: To compare the overall survival of patients with metastatic urothelial carcinoma (mUC) who failed platinum-based chemotherapy and received durvalumab or chemotherapy. / Patients & methods: In an indirect comparison of patients with mUC who failed platinum-based chemotherapy, those who received durvalumab in a single-arm study were matched to patients from the Flatiron oncology electronic medical record database who received chemotherapy (n = 158 for each cohort). Matching was based on propensity scores. Kaplan–Meier methods and Cox regression models were utilized. / Results: Median overall survival was 11.2 months (95% CI: 7.2–16.9) for durvalumab versus 8.2 months (95% CI: 6.7–9.8) for chemotherapy (hazard ratio: 0.63; 95% CI: 0.48–0.84). / Conclusion: As a second-line therapy for mUC, durvalumab was associated with longer overall survival than chemotherapy.

Type: Article
Title: Effectiveness of durvalumab versus chemotherapy in metastatic urothelial cancer: an observational, indirect comparison
Open access status: An open access version is available from UCL Discovery
DOI: 10.2217/cer-2019-0163
Publisher version: https://doi.org/10.2217/cer-2019-0163
Language: English
Additional information: Copyright © 2020 Beth L Nordstrom. This work is licensed under the Attribution-NonCommercial-NoDerivatives 4.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
Keywords: chemotherapy, durvalumab, indirect treatment comparison, observational, overall survival, urothelial carcinoma
UCL classification: UCL
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute > Research Department of Oncology
URI: https://discovery.ucl.ac.uk/id/eprint/10101053
Downloads since deposit
43Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item